The Endocrine Society and Keystone Symposia have established a collaborative series of scientific meetings that focus on the intersection of hormone signaling with major disease areas including cancer, diabetes, and cardiometabolic disease. The collaboration brings together the reputations and networks of both organizations to create coordinated programming aimed at accelerating scientific discovery and translation.
The series opens with Hormonal Influences on Immunity and Cancer Across the Lifespan, scheduled for Oct. 5–8, 2026, in Breckenridge, Colorado. Registration for this first partnered meeting is open. Following this event, the series will continue with meetings addressing diabetes and cardiometabolic disease, both planned for February 2027 in Colorado. The source did not report further logistical or program details beyond dates, locations, and that registration is available for the first meeting.
Organizers framed the meeting series around an intersectional model in which experts from multiple disciplines convene around shared topics of interest. The underlying rationale is that concentrating interactions within a single specialty can slow the pace of advancement, whereas cross-disciplinary exchange can surface new ideas, methods, and translational opportunities. The partnered meetings are intended to create forums where basic, translational, and clinical scientists consider work across systems and disease boundaries.
James Baumgartner, PhD, President and CEO of Keystone Symposia, explained that the most significant scientific progress is often found at the interfaces between disciplines and across the research-to-clinical spectrum. He argued that “biology doesn’t know any boundaries. Health and disease don’t know boundaries,” and that convening investigators from varied fields around mutual topics has produced exciting discoveries within Keystone Symposia’s programming.
Prof. Ines Pineda Torra, PhD, of Fundacion Progreso y Salud in Seville, Spain, described how interdisciplinary meetings help researchers understand the broader context of their work. According to Torra, exposure to other systems and approaches allows attendees to identify new directions for their own research and to connect disparate findings in ways that inspire fresh experiments.
Endocrine Society Past-President E. Dale Abel, MD, PhD, emphasized that the conference series creates opportunities for interaction among academic investigators, industry representatives, and innovators in therapeutics. Abel noted the value of an intimate meeting setting for facilitating substantive conversations and fostering collaborations across sectors.
Roger Cone, PhD, Mary Sue Coleman Director of the Life Sciences Institute at the University of Michigan, highlighted that the two organizations contribute complementary strengths. He said that coordinated programming between the Society and Keystone Symposia can generate new offerings that neither organization provides independently, spanning advances in basic science, translation to clinical applications, and career development pathways.
Speakers underscored a shared commitment to supporting scientists early in their careers. The partnered series is positioned as a venue where emerging investigators can meet established leaders in the field, gain visibility, access mentorship, and receive career support. Both organizations emphasized maintaining programs that offer a voice and a professional home for those building research careers.
The collaboration is designed to leverage the strengths of both partners to: convene multidisciplinary expertise, accelerate translation from bench to bedside, catalyze new collaborations across academic and industry spheres, and support career development for trainees and early-career investigators. The intersectional format is intended to help attendees see how their work fits within broader scientific and clinical contexts and to stimulate research that crosses traditional disciplinary boundaries.
Registration is currently open for the inaugural meeting, Hormonal Influences on Immunity and Cancer Across the Lifespan (Oct. 5–8, 2026, Breckenridge, Colorado). The source noted the two subsequent meetings on diabetes and cardiometabolic disease scheduled for February 2027 in Colorado. No additional program specifics, session lists, speaker rosters, or registration deadlines beyond those dates were provided in the source.